article thumbnail

Move Redesigns Realtor.com

socalTECH

which operates the online home sales site Realtor.com , said today that it has launched a redesigned site, built on a entirely new platform.

article thumbnail

Servoy Upgrades SaaS Software

socalTECH

Thousand Oaks-based Servoy , a developer of software for developing software-as-a-service applications, said Monday that it has upgraded its namesake platform.

SaaS 150
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Teledyne Buys Oceanscience

socalTECH

Thousand Oaks-based Teledyne Technologies has acquired Carlsbad-based Oceanscience Group Ltd. , a developer of unmanned marine vehicles and sensor platforms. Financial terms of the buy were not disclosed. Teledyne Technologies said the buy will help add unmanned surface vessels to its line of marine products.

article thumbnail

Xirrus Launches Chassis-based Wireless Switch

socalTECH

Thousand Oaks-based Xirrus is expanding its product line today, saying that it has launched a new, chassis based modular wireless switch. The firm said the platform allows users to upgrade radios to higher speeds, scale out radios as needed, supporting up to 32 radios in the entire platform.

article thumbnail

Amgen Re-Ups Investment In Sutro Biopharma

socalTECH

The venture capital arm of Thousand Oaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma , which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M

article thumbnail

Amgen, Illumina In Diagnostic Test Deal

socalTECH

Thousand Oaks-based Amgen and San Diego-based Illumina are in an agreement to develop and commercialize a test for metastatic colorectal cancer, Illumina said late Wednesday.

article thumbnail

Xencor, Amgen In $1.7 Billion Deal

socalTECH

Thousand Oaks-based Amgen , and Monrovia, California-based Xencor said this morning they are in a strategic collaboration worth as much as $1.7 billion based on certain regulatory and sales milestones, to combine Amgen's target discovery and protein therapeutics efforts with Xencor's XmAb b ispecific technology platform.